Since 2006, combined graft-versus-host disease (GVHD) prophylaxis with ATG Grafalon has been our department's base of peri-transplant supportive care. This recent retrospective study included 398 patients who underwent their first allogeneic hematopoietic stem cell transplantation after receiving a defined dose of ATG Grafalon. Our observations recorded reduced incidence of severe acute and chronic GVHD without negative impact on overall survival in a nonselected group with standard and uniform GVHD prophylaxis.

Department of Internal Medicine Hematology and Oncology University Hospital Brno Jihlavska 20 62500 Brno Czech Republic

School of Medicine Masaryk University Brno Czech Republic

Zobrazit více v PubMed

Penack O, Marchetti M, Ruutu T, et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European society for blood and marrow rransplantation. Lancet Haematol. 2020;7:e157–167. doi: 10.1016/S2352-3026(19)30256-X. PubMed DOI

Bonifazi F, Rubio MT, Bacigalupo A, et al. Rabbit ATG/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel. Bone Marrow Transplant. 2020;55(6):1093–1102. doi: 10.1038/s41409-020-0792-x. PubMed DOI PMC

Finke J, Bethge WA, Schmoor C, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009;10(9):855–864. doi: 10.1016/S1470-2045(09)70225-6. PubMed DOI

Remberger M, Tjønnfjord GE, Abrahamsen IW, et al. Superior graft-versus-host disease-free relapse-free survival in matched unrelated donor hematopoietic stem cell transplantation with anti-thymocyte globulin (ATG) compared to matched related donor without ATG. Transplant Cell Ther. 2021;27(7):621.e1–621.e3. doi: 10.1016/j.jtct.2021.03.019. PubMed DOI

Afram G, Simón JAP, Remberger M, et al. Reduced intensity conditioning increases risk of severe cGVHD: identification of risk factors for cGVHD in a multicenter setting. Med Oncol. 2018;35(6):79. doi: 10.1007/s12032-018-1127-2. PubMed DOI PMC

Kumar A, Reljic T, Hamadani M, Mohty M, Kharfan-Dabaja MA. Antithymocyte globulin for graft-versus-host disease prophylaxis: an updated systematic review and meta-analysis. Bone Marrow Transplant. 2019;54:1094–1106. doi: 10.1038/s41409-018-0393-0. PubMed DOI

Finke J, Schmoor C, Bethge WA, et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematol. 2017;4(6):e293–e301. doi: 10.1016/S2352-3026(17)30081-9. PubMed DOI

Walker I, Panzarella T, Couban S, et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2020;7(2):e100–e111. doi: 10.1016/S2352-3026(19)30220-0. PubMed DOI

Weisdorf D, Zhang MJ, Arora M, Horowitz MM, Rizzo JD, Eapen M. Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning. Biol Blood Marrow Transplant. 2012;18(11):1727–1733. doi: 10.1016/j.bbmt.2012.06.014. PubMed DOI PMC

Bhatt VR, Wang T, Chen K, et al. Chronic graft-versus-host disease, nonrelapse mortality, and disease relapse in older versus younger adults undergoing matched allogeneic peripheral blood hematopoietic cell transplantation: a Center for International Blood and Marrow Transplant Research analysis. Transplant Cell Ther. 2022;28(1):34–42. doi: 10.1016/j.jtct.2021.10.002. PubMed DOI PMC